Skip to content

Acute Effects of BCAA and L-Arginine on Performance in Elite Soccer Players

An Investigation of the Acute Effects of BCAA, L-Arginine, and Placebo Supplementation on Anaerobic Performance, Speed, Agility, and Recovery in Elite Soccer Players

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07347509
Acronym
CST-SP
Enrollment
21
Registered
2026-01-16
Start date
2025-01-10
Completion date
2025-09-15
Last updated
2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ergogenic Support and Performance

Keywords

Football, BCAA, L-Arginine, Performance

Brief summary

his study aims to investigate the acute effects of a single pre-exercise dose of branched-chain amino acids (BCAA) and L-arginine supplementation on anaerobic performance, sprint speed, agility, lactate response, and post-exercise heart rate recovery in male football players competing in a youth development league. Twenty-one football players participating in the T.F.F. U-19 Development League will be randomly assigned to one of three groups: BCAA (n = 7), L-arginine (n = 7), or placebo (n = 7). Participants will receive either 12 g of BCAA (4:1:1), 5 g of L-arginine, or an equivalent amount of maltodextrin, administered 1.5 hours before training. Performance assessments will include 10 m and 20 m sprint tests, an agility test, the Wingate anaerobic power test, blood lactate measurements, and post-exercise heart rate recovery measurements taken at the 1st, 3rd, and 5th minutes of recovery. Data will be analyzed using repeated measures analysis of variance to examine within- and between-group differences.Data obtained from the study were analyzed using the JASP 0.95.4 software. Pre-test and post-test values of the experimental and control groups were evaluated using Repeated Measures ANOVA. Effect size was determined using Eta Squared (η²), and differences between groups were identified using Tukey post hoc analysis. A 95% confidence interval was applied, and statistical significance was accepted at p \< 0.05. In the BCAA group, 20 m sprint performance (p \< 0.05) and agility test results (p \< 0.05) improved significantly compared to the control group. Additionally, heart rate recovery at the 3rd and 5th minutes was significantly faster in the BCAA group compared to both the L-arginine and placebo groups (p \< 0.05). In the L-arginine group, no significant improvements were observed in sprint performance, agility, lactate response, or Wingate parameters compared to placebo. No significant differences were found between groups in lactate response or anaerobic power variables (peak, mean, and minimum power, and fatigue index) (p \> 0.05). A single dose of BCAA supplementation improves short-distance sprint performance, agility, and heart rate recovery in football players; however, it does not have a significant effect on anaerobic power or lactate response. Acute L-arginine supplementation did not produce a significant ergogenic effect on these parameters. The findings suggest that amino acid supplementation may produce more pronounced effects with chronic rather than acute application

Detailed description

This study is designed as a randomized, double-blind, placebo-controlled experimental trial to examine the acute effects of branched-chain amino acid (BCAA) and L-arginine supplementation on selected performance and physiological parameters in elite youth male football players. A total of 21 male football players competing in the Turkish Football Federation (T.F.F.) U-19 Development League will be recruited for the study. Participants will be randomly allocated into three groups: BCAA supplementation group (n = 7), L-arginine supplementation group (n = 7), and placebo group (n = 7). Randomization will be performed using a computer-generated random allocation sequence. Both participants and investigators will be blinded to group assignments throughout the study. Participants in the BCAA group will receive a single oral dose of 12 g BCAA in a 4:1:1 ratio, while the L-arginine group will receive 5 g of L-arginine. The placebo group will receive an equivalent amount of maltodextrin. All supplements will be administered 1.5 hours prior to the training session under standardized conditions. Following supplementation, participants will complete a standardized warm-up protocol before undergoing performance assessments. Performance measures will include 10 m and 20 m sprint tests to assess sprint speed, an agility test to evaluate change-of-direction ability, and the Wingate anaerobic power test to assess anaerobic performance parameters. Blood lactate concentrations will be measured at specified time points, and heart rate recovery will be recorded at the 1st, 3rd, and 5th minutes following exercise. All testing procedures will be conducted under similar environmental and training conditions to minimize external variability. Data collected from the assessments will be used to examine acute physiological and performance responses to the supplementation protocols using appropriate statistical methods.

Interventions

COMBINATION_PRODUCTBCAA

A single acute oral dose of branched-chain amino acids (BCAA) administered prior to the anaerobic performance, speed, agility, and recovery tests.

DIETARY_SUPPLEMENTL-Arginine

A single acute oral dose of L-arginine administered prior to testing.

DIETARY_SUPPLEMENTbcaa and l arginine

A placebo supplement administered prior to testing.

Sponsors

Ataturk University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
19 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

Male football players aged 19 years Actively competing in a youth development or amateur football league Minimum of 3 years of regular football training experience Training at least 4 days per week Free from musculoskeletal injury in the last 6 months No use of nutritional supplements (including BCAA or L-arginine) for at least 4 weeks prior to the study Voluntary participation with written informed consent

Exclusion criteria

Presence of any cardiovascular, metabolic, neurological, or chronic disease Use of medications or supplements that may affect performance outcomes History of surgery within the last 6 months Known allergy or intolerance to BCAA or L-arginine Smoking or alcohol abuse Failure to comply with study protocol

Design outcomes

Primary

MeasureTime frameDescription
Anaerobic PerformanceImmediately after acute supplementationAnaerobic performance assessed using the Wingate Anaerobic Test.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026